Somewhat Favorable News Coverage Somewhat Unlikely to Affect Anthera Pharmaceuticals (NASDAQ:ANTH) Stock Price
News articles about Anthera Pharmaceuticals (NASDAQ:ANTH) have trended somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Anthera Pharmaceuticals earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 47.1198946580863 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- Stocks Turning into Critical Performance Analyses: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) – NASDAQ Times (nasdaqtimes.com)
- Pulmatrix, Inc. (PULM) noted a price change of -4.51% and Anthera Pharmaceuticals, Inc. (ANTH) closes with a move … – Stocks Gallery (stocksgallery.com)
- Anthera Pharmaceuticals: A Series Of Unfortunate Events – Anthera … – Seeking Alpha (seekingalpha.com)
- Versartis – Preparing To Get A Lot Bigger, Very Soon (seekingalpha.com)
- Anthera Pharmaceuticals, Inc. (ANTH) Given Consensus Rating of “Hold” by Analysts (americanbankingnews.com)
Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) opened at 1.32 on Wednesday. The stock’s market capitalization is $13.30 million. The company has a 50-day moving average of $1.57 and a 200-day moving average of $1.11. Anthera Pharmaceuticals has a 1-year low of $0.30 and a 1-year high of $3.55.
Anthera Pharmaceuticals (NASDAQ:ANTH) last released its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing the consensus estimate of ($1.47) by $0.56. On average, equities research analysts expect that Anthera Pharmaceuticals will post ($5.06) EPS for the current fiscal year.
A number of research firms have recently commented on ANTH. Jefferies Group LLC restated a “hold” rating and issued a $2.25 price target on shares of Anthera Pharmaceuticals in a report on Monday, May 15th. Zacks Investment Research raised shares of Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. Finally, ValuEngine lowered shares of Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $10.21.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.